Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3
Magali Genest, Dirk Van Lier, Theo Ikenna Uba, Anika Schroeter, Adrien Picod, Hugo Nordin, Noma Assad, Gwendolyn Marguerit, Alexis Nguyen, Andreas Bergmann, Peter Pickkers, Alexandre Mebazaa, Karine Santos, Feriel Azibani · 2026
Read Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3 by Magali Genest, Dirk Van Lier, Theo Ikenna Uba, Anika Schroeter, Adrien Picod, Hugo Nordin, Noma Assad, Gwendolyn Marguerit, Alexis Nguyen, Andreas Bergmann, Peter Pickkers, Alexandre Mebazaa, Karine Santos, Feriel Azibani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13196627.txt.
Description
Magali Genest and co-authors describe a new antibody drug aimed at shock, in this 2026 paper. A protein that normally works inside cells leaks into the blood during severe stress and tissue harm. There it disturbs vessels, the heart, and immune balance, and high levels link to organ failure.
The antibody was built from a mouse version and reshaped to fit human use. Lab tests showed tight binding to the target and no sign of harmful immune side effects from its tail end. Checks in mice and rats covered spread in the body and dose range. Early heart-failure tests in mice probed dose and safety. Human trials of the drug are now under way.
Catalog record
| CREATOR | Magali Genest, Dirk Van Lier, Theo Ikenna Uba, Anika Schroeter, Adrien Picod, Hugo Nordin, Noma Assad, Gwendolyn Marguerit, Alexis Nguyen, Andreas Bergmann, Peter Pickkers, Alexandre Mebazaa, Karine Santos, Feriel Azibani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |